BRAF and melanoma: The frequent presence of both BRAF mutations and FGF2 overexpression in melanomas, which lack a recognized systematic therapy so far, leads to the combination of FGFR inhibitor PD166866 and BRAF V600E inhibitor, consequently increased cell apoptosis and restricted tumor growth (Metzner et al., 2011).